Autor: Firma ANERGIS SA

Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy

9. Juli 2020 Firma ANERGIS SAForschung und Entwicklungadjuvants, ait, anergis, cancer, defence, helmholtz, hydroxide, hzi, mite, patients, rational, vaccine, vaccines, virometix, with

Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will Mehr